AC Immune (NASDAQ:ACIU) Downgraded to Strong Sell at ValuEngine

ValuEngine lowered shares of AC Immune (NASDAQ:ACIU) from a sell rating to a strong sell rating in a report issued on Tuesday, April 9th, ValuEngine reports.

Several other research analysts have also recently weighed in on ACIU. UBS Group started coverage on AC Immune in a research report on Friday, January 4th. They set a buy rating and a $16.00 price objective for the company. BidaskClub raised AC Immune from a buy rating to a strong-buy rating in a research report on Thursday, January 10th. Zacks Investment Research cut AC Immune from a buy rating to a hold rating in a research report on Monday, January 14th. Finally, HC Wainwright reaffirmed a buy rating and set a $18.00 price objective on shares of AC Immune in a research report on Thursday, January 24th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. AC Immune presently has a consensus rating of Hold and an average target price of $11.94.

Shares of AC Immune stock traded up $0.11 during trading hours on Tuesday, hitting $4.84. The company’s stock had a trading volume of 98,809 shares, compared to its average volume of 250,666. AC Immune has a 12 month low of $3.25 and a 12 month high of $17.40. The company has a market capitalization of $327.00 million, a P/E ratio of -5.90 and a beta of 0.01.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.77). The business had revenue of $1.41 million during the quarter, compared to the consensus estimate of $56.97 million. AC Immune had a negative return on equity of 33.97% and a negative net margin of 706.11%. On average, equities research analysts expect that AC Immune will post 0.75 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new stake in AC Immune in the third quarter valued at approximately $142,000. FMR LLC grew its position in AC Immune by 28.9% in the third quarter. FMR LLC now owns 5,209,673 shares of the company’s stock valued at $41,678,000 after acquiring an additional 1,166,524 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in AC Immune in the third quarter valued at approximately $110,000. Citadel Advisors LLC acquired a new stake in AC Immune in the third quarter valued at approximately $2,279,000. Finally, Renaissance Technologies LLC grew its position in AC Immune by 131.6% in the third quarter. Renaissance Technologies LLC now owns 52,300 shares of the company’s stock valued at $418,000 after acquiring an additional 29,720 shares in the last quarter. 30.07% of the stock is owned by hedge funds and other institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Read More: Price to Earnings Ratio (PE) Basics

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.